NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...

Key Points GAAP EPS loss was narrower than expected at $(0.79) per share for Q2 2025, compared to the estimate of $(1.01). Federal grant income totaled $1.37 million in Q2 2025, with no commercial ...

Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...

Spinal muscular atrophy (SMA) is a rare genetic condition that causes progressive muscle weakness, which, when untreated, ...

Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license ...

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Prote ...

Discover PDS Biotechnology's Q2 2025 progress on groundbreaking cancer trials, including VERSATILE-003. Explore durable outcomes and market growth potential.